{"id":"liposomal-irinotecan","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irinotecan inhibits topoisomerase I, an enzyme essential for DNA replication and transcription, causing DNA damage and cell death in rapidly dividing cancer cells. The liposomal encapsulation allows preferential accumulation in tumor tissue through enhanced permeability and retention (EPR), potentially improving the therapeutic index by reducing exposure to healthy tissues.","oneSentence":"Liposomal irinotecan is a nanoparticle formulation of the topoisomerase I inhibitor irinotecan that delivers the chemotherapy agent to tumor cells while reducing systemic toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:07.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer (in combination with fluorouracil and leucovorin)"},{"name":"Pediatric solid tumors"}]},"trialDetails":[{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT07479732","phase":"PHASE1, PHASE2","title":"Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-05","conditions":"Osteosarcoma, Osteosarcoma Metastatic","enrollment":56},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT07474103","phase":"NA","title":"SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-11-30","conditions":"Rectal Cancer, Adenocarcinoma","enrollment":49},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":"Unresectable Pancreatic Cancer","enrollment":90},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07457775","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-31","conditions":"Soft Tissue Sarcoma (Excluding GIST)","enrollment":24},{"nctId":"NCT07444918","phase":"PHASE2","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-01","conditions":"Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)","enrollment":33},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT03483038","phase":"PHASE2","title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-12-13","conditions":"Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT07432568","phase":"PHASE2","title":"A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-09","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT04150640","phase":"PHASE2","title":"Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-07-13","conditions":"Esophageal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":52},{"nctId":"NCT01356290","phase":"PHASE2","title":"Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2014-04","conditions":"Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent","enrollment":232},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT03785873","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-05-22","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":224},{"nctId":"NCT07397819","phase":"PHASE1, PHASE2","title":"Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy","status":"RECRUITING","sponsor":"Dong sheng Zhang","startDate":"2025-11-28","conditions":"Malignant Ascites","enrollment":48},{"nctId":"NCT04901702","phase":"PHASE1, PHASE2","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-06-09","conditions":"Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma","enrollment":90},{"nctId":"NCT07395063","phase":"PHASE2","title":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT06662006","phase":"PHASE2","title":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Advanced Metastatic Pancreatic Cancer","enrollment":56},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT07030283","phase":"PHASE1","title":"Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-31","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":10},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT04005339","phase":"PHASE2","title":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2019-07-29","conditions":"Advanced Biliary Tract Cancer","enrollment":48},{"nctId":"NCT07340151","phase":"NA","title":"Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT06821997","phase":"PHASE2","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-02-01","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT06375473","phase":"","title":"Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-19","conditions":"Pancreatic Cancer","enrollment":3000},{"nctId":"NCT07314385","phase":"PHASE1","title":"NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Liver Metastasis","enrollment":24},{"nctId":"NCT07235202","phase":"PHASE1, PHASE2","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","status":"RECRUITING","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","startDate":"2025-12-24","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":45},{"nctId":"NCT07281157","phase":"PHASE2","title":"Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11-01","conditions":"Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT07309289","phase":"PHASE3","title":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":144},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT04752696","phase":"PHASE2","title":"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2021-05-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT05391126","phase":"NA","title":"GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care","status":"RECRUITING","sponsor":"Reema A. Patel","startDate":"2022-09-28","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":178},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07239622","phase":"PHASE2","title":"Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Ovarian Cancer, Ovarian Clear Cell Carcinoma","enrollment":36},{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT07208539","phase":"PHASE2","title":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-10-10","conditions":"Pancreatic Cancer","enrollment":77},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT07183865","phase":"PHASE2","title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-09","conditions":"Locally Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT07173387","phase":"PHASE2","title":"Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-10-01","conditions":"Pancreatic Cancer","enrollment":42},{"nctId":"NCT05927857","phase":"PHASE1, PHASE2","title":"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2024-04-01","conditions":"Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy","enrollment":45},{"nctId":"NCT06258642","phase":"NA","title":"Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-17","conditions":"Small Cell Lung Cancer Recurrent","enrollment":39},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT05385861","phase":"PHASE1, PHASE2","title":"Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET","status":"ENROLLING_BY_INVITATION","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-08-14","conditions":"GEP-NET","enrollment":52},{"nctId":"NCT07033689","phase":"EARLY_PHASE1","title":"Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)","status":"NOT_YET_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2025-12-01","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT07123441","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sanjun Cai","startDate":"2025-09-01","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT07104604","phase":"PHASE1","title":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-08-01","conditions":"Rectal Cancer","enrollment":59},{"nctId":"NCT07099794","phase":"PHASE2","title":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":90},{"nctId":"NCT07085273","phase":"PHASE2","title":"Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-08-15","conditions":"Gastric Cancer","enrollment":33},{"nctId":"NCT07092306","phase":"PHASE2","title":"A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"Tang Xiaodong","startDate":"2025-08-10","conditions":"Ewing's Sarcoma","enrollment":74},{"nctId":"NCT07074353","phase":"PHASE3","title":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-20","conditions":"Locally Advanced Rectal Cancer","enrollment":360},{"nctId":"NCT07060014","phase":"PHASE1","title":"NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-07-18","conditions":"Advanced Small Intestine Cancer, Appendiceal Cancers","enrollment":22},{"nctId":"NCT07051785","phase":"PHASE2","title":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liu Huang","startDate":"2025-07-07","conditions":"Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT07047560","phase":"PHASE2","title":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer (CRC)","enrollment":46},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT03693677","phase":"PHASE2","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Metastatic Pancreatic Cancer","enrollment":288},{"nctId":"NCT05277766","phase":"PHASE1","title":"Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-11-21","conditions":"Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer","enrollment":45},{"nctId":"NCT03764553","phase":"PHASE2","title":"Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-05-01","conditions":"Esophageal Cancer","enrollment":320},{"nctId":"NCT07044921","phase":"PHASE2","title":"Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer Metastatic","enrollment":30},{"nctId":"NCT04901741","phase":"PHASE2","title":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"TME Pharma AG","startDate":"2026-01","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT07026123","phase":"","title":"A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Advanced Pancreatic Cancer","enrollment":40},{"nctId":"NCT04984174","phase":"","title":"Survival Rate and Treatment Cost in Patients With Pancreatic Cancer: An Analysis Using NHIS Database and K-PaC Registry Focusing on Liposomal Irinotecan","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2021-08-04","conditions":"Pancreatic Cancer","enrollment":14760},{"nctId":"NCT07020468","phase":"PHASE4","title":"Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-05-15","conditions":"Colorectal Cancer (CRC)","enrollment":57},{"nctId":"NCT05854498","phase":"PHASE2","title":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-10-13","conditions":"Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT07014540","phase":"PHASE4","title":"A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-06-20","conditions":"Neuroendocrine Carcinomas (NEC)","enrollment":45},{"nctId":"NCT07004712","phase":"PHASE2","title":"Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-06-01","conditions":"Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06827717","phase":"PHASE2","title":"Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Ewing Sarcoma","enrollment":29},{"nctId":"NCT06993025","phase":"PHASE2","title":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT06438822","phase":"PHASE2","title":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-30","conditions":"Cholangiocarcinoma","enrollment":51},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT04796948","phase":"PHASE1","title":"A Study of Irinotecan Liposome in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-08","conditions":"Advanced Pancreatic Cancer","enrollment":41},{"nctId":"NCT03328884","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-05-02","conditions":"Breast Cancer Metastatic","enrollment":55},{"nctId":"NCT03861702","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:","status":"COMPLETED","sponsor":"Nelson Yee","startDate":"2020-09-02","conditions":"Locally Advanced Pancreatic Carcinoma(LAPC)","enrollment":28},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT05457829","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-30","conditions":"Rhabdomyosarcoma, Child","enrollment":88},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT06766266","phase":"PHASE1","title":"Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-01-10","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT06894797","phase":"NA","title":"Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-01","conditions":"Locally Advanced Rectal Cancer","enrollment":68},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT06210971","phase":"PHASE2","title":"Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-02-01","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT06763029","phase":"PHASE2","title":"Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-26","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06839547","phase":"","title":"A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":"Advanced Breast Cancer Brain Metastasis","enrollment":100},{"nctId":"NCT06816914","phase":"PHASE2","title":"Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-03-05","conditions":"Resectable Pancreatic Adenocarcinoma","enrollment":84},{"nctId":"NCT03088813","phase":"PHASE3","title":"Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-04-25","conditions":"Small Cell Lung Cancer","enrollment":491},{"nctId":"NCT06578052","phase":"NA","title":"Irinotecan Liposome in Combination With Capecitabine","status":"RECRUITING","sponsor":"Junjie Hang","startDate":"2024-08-28","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06820762","phase":"PHASE2","title":"Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Dalian Medical University","startDate":"2025-02-28","conditions":"SCLC","enrollment":40},{"nctId":"NCT02631733","phase":"PHASE1","title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-05-31","conditions":"Malignant Solid Neoplasm","enrollment":18},{"nctId":"NCT05472259","phase":"PHASE2","title":"A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)","status":"RECRUITING","sponsor":"Belgian Group of Digestive Oncology","startDate":"2022-05-25","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":134}],"_emaApprovals":[],"_faersSignals":[{"count":228,"reaction":"OFF LABEL USE"},{"count":77,"reaction":"DIARRHOEA"},{"count":72,"reaction":"NEUTROPENIA"},{"count":38,"reaction":"DECREASED APPETITE"},{"count":37,"reaction":"NAUSEA"},{"count":34,"reaction":"FATIGUE"},{"count":34,"reaction":"OVERDOSE"},{"count":32,"reaction":"ASTHENIA"},{"count":32,"reaction":"LEUKOPENIA"},{"count":31,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":209,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(Onivyde®)","Nal-IRI","nal-IRI","Irinotecan Liposome","MM-398"],"phase":"phase_3","status":"active","brandName":"Liposomal irinotecan","genericName":"Liposomal irinotecan","companyName":"St. Jude Children's Research Hospital","companyId":"st-jude-children-s-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liposomal irinotecan is a small molecule that inhibits DNA topoisomerase 1, a key enzyme involved in DNA replication. It is being studied in clinical trials for various soft tissue sarcoma conditions, including adult and childhood rhabdomyosarcoma and metastatic soft tissue sarcoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}